$0.00
USD 0.00(0.00%)
1 month
Volume
Market Cap
52 Week
Prev. Close
About Imara, Inc.
Imara, Inc. engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687 is a highly selective and small molecule inhibitor of PDE9. The company was founded by James G. McArthur in 2016 and is headquartered in Cambridge, MA.
Sector
Health Technology
CEO
Rahul D. Ballal
Industry
Pharmaceuticals: Major
Exchange
NASDAQ
Website
Top Stories
Coming soon.